AMRI and Codexis Announce Technology Collaboration

              AMRI and Codexis Announce Technology Collaboration

  PR Newswire

  ALBANY, New York and REDWOOD CITY, California, Feb. 13, 2013

   - SMARTSOURCING™ Partnershipto Focus on Improved Process Development 

ALBANY, New York and REDWOOD CITY, California, Feb. 13, 2013 /PRNewswire/
--AMRI (NASDAQ: AMRI) and Codexis (NASDAQ: CDXS) announced today that they
have entered into a SMARTSOURCING™ partnership. The collaboration will provide
opportunities to combine the two companies' capabilities and technologies for
specific customer projects, yielding increased value to customers in the form
of potentially lower costs, greater yields, cleaner processes and/or faster
turnaround times.

(Logo: )

Under this non-exclusive, two-year agreement, the companies will align their
respective strengths to identify and implement new and improved manufacturing
routes for selected Active Pharmaceutical Ingredients (APIs).Combining
Codexis' directed evolution technology that enables rapid enzyme discovery and
optimization with AMRI's process development and manufacturing capabilities,
including utilizing AMRI's proprietary microbial strains, creates synergies
that will broaden both companies' ability to offer customerscost-effective,
efficient, and sustainable manufacturing processes.

"We are pleased to announce this partnership with Codexis, a company that
shares our philosophy of prioritizing scientific problem solving, innovation
and customer service," said AMRI's Chairman, President and CEO, Thomas E.
D'Ambra, Ph.D. "Combining AMRI's expertise in chemistry, biocatalysis, quality
assurance and manufacturing with Codexis' cutting-edge biocatalysis technology
and services, creates a proprietary advantage to our customer's development
projects. This is another example of the AMRI SMARTSOURCING™ strategy of
creating partnerships to deliver better outcomes to our customers."

"Codexis selected AMRI for this collaboration because AMRI understands the
opportunity to use biocatalysis for effective and comprehensive route
assessment and manufacturing," says Dr. Peter Seufer-Wasserthal, SVP
Pharmaceuticals, Codexis Inc. "Both companies have established strong
reputations in the pharmaceutical manufacturing industry. By working together,
AMRI and Codexis should identify more opportunities, which will benefit both
companies and their customers by developing innovative, cost-effective and
practical chemical processes."

About AMRI Albany Molecular Research, Inc. (AMRI) is a global contract
research and manufacturing organization offering customers fully integrated
drug discovery, development and manufacturing services. For over 21 years,
AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology
industries have undergone tremendous change in response to multiple
challenges. This experience, a track record of success and locations in the
United States, Europe and Asia now provides our customers with SMARTSOURCING™,
a full range of value-added opportunities providing customers informed
decision-making, enhanced efficiency and more successful outcomes at all
stages of the pipeline. AMRI has also successfully partnered R&D programs and
is actively seeking to out-license its remaining programs for further
development. For more information about AMRI, please visit our website at or follow us on Twitter (@amriglobal).

About Codexis Inc. Codexis, Inc. is a developer of world-leading enzymes and
processes for the production of pharmaceuticals, biofuels and bio-based
chemicals. Codexis' product lines include CodeXyme™ cellulase enzymes and
CodeXol™ detergent alcohol. Partners and customers include global leaders such
as Merck, Pfizer and Arch Pharmalabs. For more information, see .

Contact: AMRI: Investors: Michael Nolan, AMRI Chief Financial Officer,
+1-518-512-2261, or Media: Gina Monari, AMRI Communications, +1-518-512-2512;
or Codexis, Inc.: Investors: +1-212-362-1200,, or Media:
Press spacebar to pause and continue. Press esc to stop.